-
Mashup Score: 1
NEW ORLEANS — In a phase 2 trial, an oral PCSK9 inhibitor lowered LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks, researchers reported at the American College of Cardiology Scientific Session.For the phase 2b, randomized, double-blind, placebo-controlled trial, researchers evaluated safety and efficacy of the oral PCSK9 inhibitor (MK-0616, Merck) in patients
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Categories: Endocrinology, Latest HeadlinesTweet-
In the February Issue: Long-term efficacy and safety of #inclisiran in patients with high #cardiovascular risk and elevated LDL #cholesterol (#ORION-3): results from the 4-year open-label extension of the ORION-1 trial https://t.co/uwxyZyIpNK #PCSK9 inhibitor #OpenAccess
-
-
Mashup Score: 0ORION-3: delivering lipid lowering treatment for longer - 1 year(s) ago
The importance of LDL cholesterol in atherosclerotic cardiovascular disease (ASCVD) is highlighted by countless studies establishing its role in disease causality and clinical trials showing a direct association between lowering LDL cholesterol and reductions in cardiovascular risk. Although treatment guidelines have increasingly emphasised the importance of lipid lowering in cardiovascular…
Categories: Endocrinology, Latest HeadlinesTweet-
Linked Comment by Stephen J Nicholls: #ORION-3: delivering #lipid lowering treatment for longer https://t.co/OxmWqWEWJT #PCSK9 inhibitor #FREE to read with registration (also FREE)
-
-
Mashup Score: 2
“PCSK9 inhibition may represent a novel therapeutic pathway in addition to currently recommended therapeutic approaches for severe COVID-19.”
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Patients hospitalized with severe #COVID19 treated with an injection of #PCSK9 were less sick and had a higher survival rate than patients given a placebo, according to a report in #JACC. Get the details in @MDedgeCardio: https://t.co/G6daOVJTIX
-
-
Mashup Score: 0The Lancet Diabetes & Endocrinology, February 2023, Volume 11, Issue 2, Pages 63-138, e2 - 1 year(s) ago
Explore the current issue of The Lancet Diabetes & Endocrinology, a monthly journal focussed on diabetes, endocrinology, and metabolism
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
The February Issue of @TheLancetEndo is now online, featuring #T1D in #pregnancy, #insulin, #rtCGM, #PCSK9 inhibitor, #cholesterol, #dyslipidaemia, #LongCovid, #glucagon #centenary, #diabetes #registries, #vitaminD, #teplizumab, #LivedExperiences & more https://t.co/ft8CFDfqG7 https://t.co/sIPuGMaDNs
-
-
Mashup Score: 14
Abstract Background The intensity of inflammation during COVID-19 is related to adverse outcomes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in low-density lipoprotein recept…
Categories: Expert Picks, Latest HeadlinesTweet-
First randomized trial showing sig. ⬇️ death or intubation at 30 days & ⬇️ circulating IL-6 levels w/ #PCSK9 inhibitor in patients w/ severe #COVID19. Patients w/ more intense inflammation at baseline had ⬆️ survival w/ PCSK9 inhibition vs placebo. https://t.co/jp8R8m4MQF #JACC https://t.co/dYMds8pcsi
-
-
Mashup Score: 0
Abstract Background The intensity of inflammation during COVID-19 is related to adverse outcomes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in low-density lipoprotein recept…
Categories: Cardiologists, Latest HeadlinesTweet-
#PCSK9 inhibition compared with placebo reduced ⤵️ the primary endpoint of death or need for intubation and IL-6 levels in severe #COVID-19 https://t.co/fH7T9qaZB7 via @JACCJournals @NYUCVDPrevent @PCSK9Forum @ACCinTouch https://t.co/sB4e9X5jlo
-
-
Mashup Score: 5PCSK9 Inhibitors for Severe COVID? Pilot Trial Signals Benefit - 1 year(s) ago
The drugs’ effects go beyond LDL-lowering in ways that might potentially benefit hospitalized patients with COVID-19, at least those who are sickest, preliminary results suggest.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A new #JACC study found that patients hospitalized with severe #COVID19 who received an injection of a #PCSK9 inhibitor were less sick and had a higher survival rate. Read more in @Medscape: https://t.co/Y2wsfR47hp
-
-
Mashup Score: 0
The preliminary findings suggest PCSK9 inhibition has anti-inflammatory effects relevant in COVID-19 and beyond.
Source: TCTMD.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
According to a study in #JACC, #PCSK9 inhibitors are linked with better short-term outcomes for patients hospitalized with severe #COVID19. Get the details with @ToddNeale in @TCTMD: https://t.co/lGtcsq4ZES #CardioTwitter
-
-
Mashup Score: 0
Taking proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors was associated with lower rates of death and fewer instances of intubation among patients with severe cases of COVID-19, according to a new study in the Journal of the American College of Cardiology.[1] Increase in COVID-19 survival rates with PCSK9 inhibitors Sometimes used for cholesterol management, PCSK9 inhibitors…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#PCSK9 inhibitors were associated with a reduced rate of death & less instances of intubation among patients with severe #COVID19, according to a new study in #JACC. Read more in @CardioBusiness: https://t.co/YU78Pmbegw
-
In a phase 2 trial, an oral #PCSK9 inhibitor lowered #LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks @CBallantyneMD @bcmhouston @ACCinTouch #ACC23 #Cardiotwitter https://t.co/r8XV6eqDVO